Your browser doesn't support javascript.
loading
POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33.
Hitomi, Yuki; Ueno, Kazuko; Kawai, Yosuke; Nishida, Nao; Kojima, Kaname; Kawashima, Minae; Aiba, Yoshihiro; Nakamura, Hitomi; Kouno, Hiroshi; Kouno, Hirotaka; Ohta, Hajime; Sugi, Kazuhiro; Nikami, Toshiki; Yamashita, Tsutomu; Katsushima, Shinji; Komeda, Toshiki; Ario, Keisuke; Naganuma, Atsushi; Shimada, Masaaki; Hirashima, Noboru; Yoshizawa, Kaname; Makita, Fujio; Furuta, Kiyoshi; Kikuchi, Masahiro; Naeshiro, Noriaki; Takahashi, Hironao; Mano, Yutaka; Yamashita, Haruhiro; Matsushita, Kouki; Tsunematsu, Seiji; Yabuuchi, Iwao; Nishimura, Hideo; Shimada, Yusuke; Yamauchi, Kazuhiko; Komatsu, Tatsuji; Sugimoto, Rie; Sakai, Hironori; Mita, Eiji; Koda, Masaharu; Nakamura, Yoko; Kamitsukasa, Hiroshi; Sato, Takeaki; Nakamuta, Makoto; Masaki, Naohiko; Takikawa, Hajime; Tanaka, Atsushi; Ohira, Hiromasa; Zeniya, Mikio; Abe, Masanori; Kaneko, Shuichi.
Afiliação
  • Hitomi Y; Department of Human Genetics, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan.
  • Ueno K; Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
  • Kawai Y; Graduate School of Medicine, Tohoku University, Sendai, Japan.
  • Nishida N; Department of Human Genetics, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan.
  • Kojima K; The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan.
  • Kawashima M; Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
  • Aiba Y; Graduate School of Medicine, Tohoku University, Sendai, Japan.
  • Nakamura H; Japan Science and Technology Agency (JST), Tokyo, Japan.
  • Kouno H; Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Omura, Japan.
  • Kouno H; Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Omura, Japan.
  • Ohta H; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Sugi K; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Nikami T; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Yamashita T; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Katsushima S; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Komeda T; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Ario K; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Naganuma A; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Shimada M; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Hirashima N; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Yoshizawa K; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Makita F; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Furuta K; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Kikuchi M; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Naeshiro N; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Takahashi H; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Mano Y; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Yamashita H; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Matsushita K; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Tsunematsu S; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Yabuuchi I; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Nishimura H; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Shimada Y; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Yamauchi K; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Komatsu T; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Sugimoto R; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Sakai H; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Mita E; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Koda M; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Nakamura Y; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Kamitsukasa H; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Sato T; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Nakamuta M; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Masaki N; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Takikawa H; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Tanaka A; Headquarters of PBC Research in NHO Study Group for Liver Disease in Japan (NHOSLJ), Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan.
  • Ohira H; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Zeniya M; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Abe M; Department of Gastroenterology and Rheumatic Diseases, Fukushima Medical University of Medicine, Fukushima, Japan.
  • Kaneko S; Department of Gastroenterology and Hepatology, Tokyo Jikei University School of Medicine, Tokyo, Japan.
Sci Rep ; 9(1): 102, 2019 01 14.
Article em En | MEDLINE | ID: mdl-30643196
Primary biliary cholangitis (PBC) is a chronic and cholestatic autoimmune liver disease caused by the destruction of intrahepatic small bile ducts. Our previous genome-wide association study (GWAS) identified six susceptibility loci for PBC. Here, in order to further elucidate the genetic architecture of PBC, a GWAS was performed on an additional independent sample set, then a genome-wide meta-analysis with our previous GWAS was performed based on a whole-genome single nucleotide polymorphism (SNP) imputation analysis of a total of 4,045 Japanese individuals (2,060 cases and 1,985 healthy controls). A susceptibility locus on chromosome 3q13.33 (including ARHGAP31, TMEM39A, POGLUT1, TIMMDC1, and CD80) was previously identified both in the European and Chinese populations and was replicated in the Japanese population (OR = 0.7241, P = 3.5 × 10-9). Subsequent in silico and in vitro functional analyses identified rs2293370, previously reported as the top-hit SNP in this locus in the European population, as the primary functional SNP. Moreover, e-QTL analysis indicated that the effector gene of rs2293370 was Protein O-Glucosyltransferase 1 (POGLUT1) (P = 3.4 × 10-8). This is the first study to demonstrate that POGLUT1 and not CD80 is the effector gene regulated by the primary functional SNP rs2293370, and that increased expression of POGLUT1 might be involved in the pathogenesis of PBC.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polimorfismo de Nucleotídeo Único / Glucosiltransferases / Cirrose Hepática Biliar Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Sci Rep Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polimorfismo de Nucleotídeo Único / Glucosiltransferases / Cirrose Hepática Biliar Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Sci Rep Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão País de publicação: Reino Unido